Enliven Therapeutics Inc [ELVN] stock prices are up 10.79% to $17.97 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ELVN shares have gain 4.54% over the last week, with a monthly amount drifted -14.75%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Enliven Therapeutics Inc [NASDAQ: ELVN] stock has seen the most recent analyst activity on December 13, 2024, when BTIG Research initiated its Buy rating and assigned the stock a price target of $42. Previously, H.C. Wainwright started tracking the stock with Buy rating on September 09, 2024, and set its price target to $37. On June 11, 2024, Robert W. Baird initiated with a Outperform rating and assigned a price target of $32 on the stock. Mizuho started tracking the stock assigning a Buy rating and suggested a price target of $34 on April 09, 2024. Jefferies initiated its recommendation with a Buy and recommended $27 as its price target on March 29, 2023.
The stock price of Enliven Therapeutics Inc [ELVN] has been fluctuating between $13.30 and $30.03 over the past year. Currently, Wall Street analysts expect the stock to reach $39.5 within the next 12 months. Enliven Therapeutics Inc [NASDAQ: ELVN] shares were valued at $17.97 at the most recent close of the market. An investor can expect a potential return of 119.81% based on the average ELVN price forecast.
Analyzing the ELVN fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.27, Equity is -0.29 and Total Capital is -0.34.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.87 points at the first support level, and at 15.77 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.65, and for the 2nd resistance point, it is at 19.32.
Ratios To Look Out For
It’s worth pointing out that Enliven Therapeutics Inc [NASDAQ:ELVN]’s Current Ratio is 19.99. Also, the Quick Ratio is 19.99, while the Cash Ratio stands at 7.8.
Transactions by insiders
Recent insider trading involved Kintz Samuel, PRESIDENT AND CEO, that happened on Apr 17 ’25 when 5000.0 shares were sold. Officer, Lyssikatos Joseph P completed a deal on Apr 21 ’25 to buy 5000.0 shares. Meanwhile, Officer Kintz Samuel bought 5000.0 shares on Apr 17 ’25.
